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ORIGINAL ARTICLE
Comprehensive gene expression proﬁling and
immunohistochemical studies support application of
immunophenotypic algorithm for molecular subtype classiﬁcation
in diffuse large B-cell lymphoma: a report from the International
DLBCL Rituximab-CHOP Consortium Program Study
C Visco1,2, Y Li3, ZY Xu-Monette1, RN Miranda1, TM Green4, Y Li5, A Tzankov6, W Wen3, W-m Liu3, BS Kahl7, ESG d’Amore2,
S Montes-Moreno8, K Dybkær9, A Chiu10, W Tam11, A Orazi11, Y Zu12, G Bhagat13, JN Winter14, H-Y Wang15, S O’Neill16, CH Dunphy16,
ED Hsi17, XF Zhao18, RS Go19, WWL Choi20, F Zhou21, M Czader22, J Tong23, X Zhao23, JH van Krieken24, Q Huang25, W Ai26, J Etzell26,
M Ponzoni27, AJM Ferreri27, MA Piris8, MB Møller4, CE Bueso-Ramos1, LJ Medeiros1, L Wu3 and KH Young1
Gene expression proﬁling (GEP) has stratiﬁed diffuse large B-cell lymphoma (DLBCL) into molecular subgroups that correspond to
different stages of lymphocyte development–namely germinal center B-cell like and activated B-cell like. This classiﬁcation has
prognostic signiﬁcance, but GEP is expensive and not readily applicable into daily practice, which has lead to immunohistochemical
algorithms proposed as a surrogate for GEP analysis. We assembled tissue microarrays from 475 de novo DLBCL patients who were
treated with rituximab-CHOP chemotherapy. All cases were successfully proﬁled by GEP on formalin-ﬁxed, parafﬁn-embedded
tissue samples. Sections were stained with antibodies reactive with CD10, GCET1, FOXP1, MUM1 and BCL6 and cases were classiﬁed
following a rationale of sequential steps of differentiation of B cells. Cutoffs for each marker were obtained using receiver-operating
characteristic curves, obviating the need for any arbitrary method. An algorithm based on the expression of CD10, FOXP1 and BCL6
was developed that had a simpler structure than other recently proposed algorithms and 92.6% concordance with GEP. In
multivariate analysis, both the International Prognostic Index and our proposed algorithm were signiﬁcant independent predictors
of progression-free and overall survival. In conclusion, this algorithm effectively predicts prognosis of DLBCL patients matching GEP
subgroups in the era of rituximab therapy.
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INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL), not otherwise speciﬁed, is
classiﬁed by the World Health Organization (WHO) as a single-
disease entity on the basis of morphological and clinical criteria.1
The standard therapy for patients with DLBCL is rituximab
combined with cyclophosphamide, doxorubicin, vincristine and
prednisone (R-CHOP), and this results in a long-term disease-free
survival of B50%.2 Gene expression proﬁling (GEP), however, has
identiﬁed molecularly and clinically distinct subgroups of disease
within DLBCL, known as germinal center B-cell like (GCB) and
activated B-cell like (ABC), and unclassiﬁed DLBCL.3,4 The DLBCL
gene-expression subgroups differ by the expression of more than
1000 genes, making them at this level as different as acute
lymphoid and myeloid leukemias.5 The mechanisms of malignant
transformation of the two subgroups involve distinct and speciﬁc
pathways, with BCL2 rearrangement and C-REL ampliﬁcation seen
mostly in GCB–DLBCL and constitutive activation of the NF-kB
pathway characterizing ABC-DLBCL.4,6 These novel insights into
the pathogenesis of the DLBCL subgroups are enabling the
discovery of targets for investigational therapies.
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The molecular distinction between the DLBCL subgroups is also
important, because patients in these subgroups respond differ-
ently and retain a different prognosis when treated with R-CHOP.7
Patients with GCB–DLBCL have a more favorable outcome than
those with ABC-DLBCL, irrespective of the International Prognostic
Index (IPI) score.8 However, because of expense and technical
constraints and the need for intensive bioinformative analysis, the
use of GEP technology for routine clinical use is challenging. In an
attempt to translate GEP classiﬁcation into a manageable set of
measurable proteins, several algorithms have been proposed in
recent years based on immunohistochemical stains and tissue
microarray (TMA) technique. The original algorithm, proposed by
Hans et al,9 is based on the expression of three proteins: neprilysin
or common acute lymphocytic leukemia antigen (CD10), B-cell
lymphoma 6 (BCL6) and multiple myeloma oncogene 1/interferon
regulatory factor 4 (MUM1/IRF4) and can classify DLBCL patients
into two categories (GCB and non-GCB) with differing prognoses.
This algorithm, however, was created for use in patients treated
with CHOP without rituximab, and in addition, it had low
concordance with GEP analysis (71% for GCB, 88% for non-GCB).
The prognostic relevance of the Hans algorithm led to inconsistent
results in subsequent studies performed in patient groups treated
with R-CHOP.7,10–15
Three studies reported new staining algorithms obtained from
patients treated with R-CHOP,12,15,16 two of which combined results
with GEP analysis.12,16 In the ﬁrst study, Choi et al.12 developed an
algorithm based on the expression of ﬁve biomarkers, which had a
high concordance with GEP (93%). Compared with the Hans
algorithm, the Choi algorithm integrated the analysis of two new
molecules: forkhead box protein P1 (FOXP1) and serpin A9/germinal
center expressed transcript 1 (GCET1), that allowed a better
discrimination between GCB and non-GCB–DLBCL. These two
markers exhibited reliable staining17–19 and could further address
different steps of B-cell maturation. In a second study, Meyer et al.16
reported an algorithm (called the ‘Tally’ algorithm) that had a high
concordance with GEP and was also based on the expression of ﬁve
markers: CD10, GCET1, FOXP1, MUM1 and rhombotin-2/LIM domain
only 2 (LMO2). However, based on a recent study, when these
algorithms were tested for concordance with GEP and prognostic
power on an independent cohort of patients, they did not correlate
well with GEP results and showed poor prognostic power.20
We used ﬁve speciﬁc markers, including CD10, GCET1, FOXP1,
MUM1 and BCL6 to describe consecutive stages of the differentia-
tion of mature B cells through the GC. We constructed an effective
algorithm, deﬁned as Visco-Young algorithm, based on three of
these markers that can match with high concordance (92.6%)
between patients with GCB and ABC gene signatures.
Our algorithm exhibits strong independent prognostic value that
is almost equivalent to that of GEP analysis in a large cohort of
DLBCL patients treated with R-CHOP.
PATIENTS AND METHODS
Patients
We studied 475 patients with de novo adult DLBCL cases that had been
diagnosed between January 2002 and October 2009, as part of the
International DLBCL Rituximab-CHOP Consortium Program Study. Cases
were selected on the basis of the available GEP results and clinical data. All
cases were reviewed by a group of hematopathologists (all primary center
pathologists, SMM, MAP, MBM, AT and KHY), and the diagnoses were
conﬁrmed on the basis of WHO classiﬁcation criteria. The current study was
reviewed and approved as being of minimal to no risk or as exempt by
each of the participating center Institutional Review Boards, and the
comprehensive collaborative study was approved by the Institutional
Review Board (IRB) at The University of Texas MD Anderson Cancer Center
in Houston, Texas. A Material Transfer Agreement (MTA) was established
and approved by each of the participating centers joining this
collaborative project for the International DLBCL Consortium Program.
TMA immunohistochemistry
Immunohistochemical staining was performed on all 475 cases. The
hematoxylin-eosin stained slides from each tumor were reviewed, and
representative areas with the highest percentage of tumor cells were
selected for TMA construction. Immunohistochemical analysis was performed
on 4-mm TMA sections using a streptavidin–biotin complex technique, and
antibodies reactive against the following antigens were utilized: CD3, CD5,
CD10, CD20, CD30, CD79a, CD138, ALK-1, BCL2, BCL6, FOXP1, GCET1, GCET2
and MUM1. The samples were analyzed independently by a group of six
hematopathologists/pathologists in addition to each of the contributing
center hematopathologists, and disagreements were resolved by joint
review on a multiheaded microscope.
GEP analysis
RNA was extracted from 475 formalin-ﬁxed, parafﬁn-embedded tissue
samples using HighPure Parafﬁn RNA Extraction Kit (Roche Applied
Science, Indianapolis, IN, USA). Fifty nanogram RNA was transcribed into
cDNA, linearly ampliﬁed using the WT-Ovation FFPE System (Nugen) SPIA
method,21 and biotin labeled using FL-Ovation cDNA Biotin Module V2
(Nugen) in all the cases. For GeneChip hybridization, 5 mg of WT-Ovation
ampliﬁed cDNA was applied to HG-U133 Plus 2.0 GeneChips (Affymetrix,
Santa Clara, CA, USA) and hybridized overnight. GeneChips were washed,
stained and scanned using the Fluidic Station 450 and GeneChip Scanner
3000 (Affymetrix) according to the manufacturer’s recommendations. For
data analysis and classiﬁcation, the microarray DQN (trimmed mean of
differences of perfect match and mismatch intensities with quantile
normalization22) signals were generated and normalized to the quantiles
of beta distribution with parameters P¼ 1.2 and q¼ 3. A Bayesian model23
was also utilized to determine the class probability. The classiﬁcation model
was built on the 47 paired formalin-ﬁxed, parafﬁn-embedded tissue-fresh
frozen sample data set previously generated with conﬁdence of 90–100% for
both fresh frozen tissue and FFPE tissue.24 The same methodology developed
during this pilot study has been validated and demonstrated to be applicable
by using the LLMPP data set in the Gene Expression Omnibus database GSE#
10846 that have 181 CHOP-treated and 233R-CHOP-treated DLBCL patients
with FF samples.25
Receiver-operating characteristic (ROC) curve analysis to assess
discriminatory accuracy of each marker
The ROC curves allowed us to visualize the speciﬁcity and sensitivity of
each marker (CD10, GCET1, FOXP1, MUM1 and BCL6) in assigning cases to
GCB or ABC classiﬁcation before further categorization.26 The performance
of each marker could be quantiﬁed by the area under the ROC curve
(Supplementary Figure 1). All cases were classiﬁed separately as GCB or
non-GCB based on the cutoff scores from both data sets and the proposed
three-marker algorithm. Except for eight cases (1.7%), which were classiﬁed
as GCB according to the cutoff scores from set 2 but not from set 1 due to
the lower cutoff for BCL6, all other 467 cases were completely matched
between both groups (k¼ 0.978), demonstrating the validity and reliability
of our model. Of these eight cases, six (all six being CD10-negative) were
GCB and two ABC according to GEP, indicating that the lower (30%) cutoff
score for BCL6 is more sensitive and useful to identify those, especially
CD10-negative GCB cases.
Rationale for the structure of the algorithm
In designing the algorithm, we emphasized the importance of CD10
expression (step 1), which is usually part of the initial diagnostic staining
panel for hematopathologists, and its staining has shown the best
concordance in different studies between different laboratories.27 We then
analyzed GCET1, FOXP1 and MUM119,28 expression in this order (step 2–4),
following our rationale that will be discussed below. Finally, we left to BCL6
a minor role in recognizing patients with GCB–DLBCL (step 5) because of
the variability and reliability of its staining.26 The ﬁve steps of the global
algorithm are shown in Figure 1.
Cutoff establishment
We avoided cutoff values based on mean and median expression, as our
protein marker expression had a non-Gaussian distribution (Table 1).
Instead, by calculating the Youden index29 from our ROC curves, we
identiﬁed the point on the curve corresponding to the maximum
sensitivity and speciﬁcity for each marker to classify a DLBCL as either of
GCB or ABC type according to GEP analysis. The Youden index pointed to
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optimal cutoff scores of 35% for CD10, 33% for BCL6, 45% for GCET, 75%
for FOXP1 and 58% for MUM1. For CD10 and BCL6, the cutoffs were very
close to 30%, which is the accepted cutoff for these two molecules.9 In
order to avoid too many different cutoffs in the ﬁnal algorithm, we
compared the optimal cutoff of GCET1 and FOXP1 to 60% and found no
change occurred in their sensitivity and speciﬁcity. Therefore, we modiﬁed
the cutoff scores for both GCET1 and FOXP1 to 60%, thus maintaining the
optimal cutoff for MUM1.
Reﬁning the global algorithm
The initial algorithm with the established cutoffs exhibited a straightfor-
ward concordance with GEP analysis (Figure 1). This concordance could be
further improved by removing unnecessary passages or redundant
decisional points. We removed all the subsequent steps for CD10þ
patients and we eliminated step 4 (MUM1), obtaining a four-marker
algorithm, which is shown in Figure 2a. Furthermore, after removing step 2
(GCET1) for CD10 patients, we obtained a three-marker algorithm, shown
in Figure 2b. By simplifying the algorithm, we increased the number of
concordant patients.
Validation set
To test the efﬁcacy of the new algorithm in predicting survival in an
independent series of cases, we applied the algorithm to a second group
of 574 archival DLBCL cases studied using TMAs similarly to the ﬁrst cohort
but for which no GEP analysis was available. Of these, 237 patients had
been treated with R-CHOP and 337 with CHOP without rituximab. The
same selection criteria as those for the ﬁrst cohort were applied to these
patients. Clinical characteristics at presentation for the validation set were
similar to the test set in terms of median gender (female in 45%, P¼ 0.37),
lactate dehydrogenase (elevated in 34%, P¼ 0.66), AAS (III–IV in 49%,
P¼ 0.28), presence of B symptoms (32%, P¼ 0.77) or IPI
(0–2 in 64%, P¼ 0.69), except for age. Patients of the validation set were
signiﬁcantly younger than patients of the test set (median age 58 years,
P¼ 0.007).
Fluorescence in situ hybridization for MYC gene rearrangement
Fluorescence in situ hybridization was performed on parafﬁn-embedded
tissue sections with a locus-speciﬁc identiﬁer IGH/MYC/CEP 8 tri-color, dual
fusion probes (05J75-001 from Vysis, Downers Grove, IL, USA) and, due to
shortcommings of the former in identifying alternative (non-IGH) MYC
rearrangement partners, a locus-speciﬁc identiﬁer MYC dual-color,
break-apart probe (BP, 05J91-001 from Vysis). Fluorescence in situ
hybridization signals were scored with a Zeiss ﬂuorescence microscope
(Carl Zeiss, Dublin, CA, USA). Cases on the TMA were considered for
evaluation if at least 200 tumor cell nuclei per core displayed positive
signals. Abnormal ﬂuorescence in situ hybridization signals were recorded
as percentage of cells showing an abnormality.
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Figure 1. Stratification of 475 diffuse large B-cell lymphoma (DLBCL) patients using TMA immunohistochemistry: initial global algorithm.
This algorithm illustrates our rationale for the sequential steps of differentiation of the B cells through the GC and is built on data from 475
patients. Values in parentheses indicate how patients were classified according to GEP analysis; uncl, unclassifiable cases. The first value in the
parentheses indicates the number of cases where GEP and TMA coincided.
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Response deﬁnitions and statistical analysis
Response assessment was standardized among different Institutions
following the criteria based on CT-scan and bone marrow biopsy.30 Late
deaths not related to the underlying lymphoma or its treatment were not
considered treatment failures.30 The actuarial probability of progression-
free survival (PFS) and overall survival (OS) was determined using the
Kaplan–Meier method,31 and differences were compared using the log-
rank test. A Cox proportional-hazards model was used for multivariate
analysis.32 All variables with Po0.05 were considered to be statistically
signiﬁcant. The comparison of clinical and laboratory features at
presentation was carried out with the w2-test or the Spearman’s rank
correlation.
RESULTS
Comparison between the new algorithms and GEP results
The 475 patients were classiﬁed into GCB (231, 49%), ABC
(200, 42%) or unclassiﬁable (44, 9%) cases by GEP analysis, as
shown in Figure 3. The three-marker algorithm (Figure 2b)
exhibited a very similar concordance to GEP analysis compared
with the four-marker algorithm (only one additional mismatch;
see Table 1). Hence, this simpliﬁed version was adopted for
subsequent analysis. According to the three-marker algorithm, 252
patients (53%) had a GCB phenotype and 223 (47%) had a non-
GCB phenotype (Figure 2b). The 44 cases that were unclassiﬁable
by GEP were assigned to the GCB (21) or the non-GCB (23)
Table 1. Concordance between GEP analysis and 4 immunohisto-
chemical algorithms in 431 patients who were classified by GEP either
as GCB or ABC (excluding 44 unclassified patients)
Algorithms GEP analysis Concordance
(%)
GCB ABC
(231) (200)
Three-marker algorithm
(Visco-Young algorithm)
GCB 215 16 93.1
Non-GCB 16 184 92.0
Four-marker algorithm
(Visco-Young algorithm)
GCB 216 16 93.2
Non-GCB 15 184 92.5
Choi algorithm
GCB 216 28 88.6
Non-GCB 15 172 91.9
Hans algorithm
GCB 209 33 86.3
Non-GCB 22 167 88.3
Abbreviations: ABC, activated B-cell like; GCB, germinal center B-cell like;
GEP, gene expression profiling.
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Figure 2. Stratification of 475 DLBCL patients using TMA immunohistochemistry: proposed three-marker and four-marker algorithms
compared with the Choi and Hans algorithms. (a) The four-marker algorithm was developed from the initial global algorithm using four
markers and correctly characterizes 92.8% of patients as either GCB- or ABC-DLBCL according to GEP analysis. (b) The three-marker algorithm
represents a further simplification and characterizes 92.6% patients compared with GEP. (c) The Choi algorithm was developed with the same
five markers as those in our initial global algorithm but with different cutoffs and sequences, and had a predictivity of 90.1% compared with
GEP. (d) The Hans algorithm was based on the expression of three markers and had a predictivity of 87.3% compared with GEP. Values in the
parentheses indicate how patients were classified according to GEP analysis; uncl, unclassifiable cases.
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subgroups by the new algorithm. Our algorithm had a con-
cordance with GEP results of 92.6% for the 431 patients classiﬁed
by GEP as having either GCB or ABC disease, compared with 92.8%
for the four-marker algorithm. The Choi and Hans algorithms
could correctly assign 90.1% and 87.3% of the cases, respectively
(Table 1). Concordance of the three-marker algorithm was 93.1%
for GCB (16 mismatches out of 231 patients) and 92% for ABC (16
mismatches out of 200 patients), both of which compared
favorably with the Hans and Choi algorithms (Table 1). The ‘Tally’
algorithm proposed by Meyer et al.16 was applied to 342 patients
whose samples could be classiﬁed without the need
for LMO2 staining, and its concordance with GEP was 90.1%.
The concordance of our algorithm with the recently proposed
simpliﬁed Hans* and Choi* algorithms by Meyer et al.16 was 86.3%
and 81.2%, respectively.
Distribution and prognostic signiﬁcance of the expression
of each marker
With the Youden index, we established the positivity cutoffs of
30% or more for CD10 and BCL6 and 60% or more for GCET1,
FOXP1 and MUM1. Expression above these cutoffs for CD10 was
observed in 190 (40%) of patients, BCL6 in 375 (79%), GCET1 in
134 (28%), FOXP1 in 271 (57%) and MUM1 in 179 (38%).
The distribution of the expression for each marker is shown in
the histograms on Table 2. As the cutoffs determined with the
Youden index were meant only to determine patients as having
either GCB or non-GCB–DLBCL and were not intended for
predicting survival, we divided the percentage of expression of
each marker in percentiles in the 475 R-CHOP-treated patients.
As shown in Table 2, CD10 expression was signiﬁcantly associated
with PFS when 0, 20 or 30% were used as cutoffs. BCL6 expression
did not affect PFS. GCET1 and MUM1 expression were instead
signiﬁcantly associated with PFS at several cutoffs, with the
Youden index and our chosen cutoffs being among the most
predictive for PFS. The 60% cutoff for FOXP1 was the most
predictive for PFS in this study group.
Clinical data and survival
Clinical characteristics at presentation for the 475 R-CHOP-treated
patients with de novo DLBCL and stratiﬁed according to our
proposed three-marker algorithm are shown in Table 3. Clinical
variables were well balanced between GCB and non-GCB
subgroups except for age, stage and IPI scores. Patients with the
non-GCB phenotype were signiﬁcantly older (median age, 65 vs 60
years) and had higher IPI scores (37% vs 22%; IPI 3–5) than
patients with the GCB phenotype, as shown in Table 3.
Median follow-up was 42 months (range, 4–106 months).
Overall, the 5-year OS and PFS were 62% and 60%, respectively
(Figures 4a and 4b). No different outcome was observed in patients
treated in different Institutions. As shown in Figures 4c 5-year OS
was signiﬁcantly different when patients were stratiﬁed according
to GEP subgroups (69±3% for GCB vs 53±5% for ABC vs 60±4%
for unclassiﬁed cases; P¼ 0.02 for GCB vs ABC). Similarly, the
5-year OS was signiﬁcantly different when patients were stratiﬁed
according to our three-marker algorithm (71±3% for GCB vs
51±5% for non-GCB; P¼ 0.003, Figure 4d). In terms of PFS, Figures
4e and f show that both the GEP (64±3% for GCB vs 46±5% for
ABC vs 53±5% for unclassiﬁed; P¼ 0.003 for GCB vs ABC) and our
algorithm (64±4% for GCB vs 48±5% for non-GCB; P¼ 0.002) can
stratify patients into groups with signiﬁcantly different 5-year PFS
rates. As there were 44 unclassiﬁed cases by GEP and they would
not be excluded in the clinical setting, the use of our algorithm
allowed us to stratify this subset into two groups with distinct OS
and PFS rates. These rates were nonetheless not signiﬁcantly
different which we believe can be attributed to the small number
of cases (Supplementary Figure 2). In terms of OS and PFS, the
new algorithm compared favorably both with the Choi and Hans
algorithms. Five year OS was 65±4% for GCB vs 54±5% for non-
GCB (P¼ 0.04) and 5-year PFS was 66±3% for GCB vs 53±5% for
non-GCB (P¼ 0.02), according to the Choi algorithm. Using
the Hans algorithm, 5-year OS was 64±4% for GCB vs 55±4%
for non-GCB (P¼ 0.06), and 5-year PFS was 67±4% vs 52±5%
(P¼ 0.02). The ‘Tally’ algorithm16 was signiﬁcantly predictive for
OS (P¼ 0.009) and PFS (P¼ 0.01).
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Figure 3. Heat map of hierarchical clustering of GEP on 475 DLBCL patients. Cases stratified as ABC-DLBCL on the left show all the cases
express selected markers. Similarly, cases stratified as GCB–DLBCL on the right express hierarchically selected markers. Cases in the middle
could not be stratified by GEP and considered as unclassifiable cases (UC).
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In the validation set of 574 patients with available TMA data but
without GEP analysis, we conﬁrmed the reliability of our algorithm
in predicting survival. In this independent subset of patients who
were treated with either CHOP or R-CHOP, our algorithm could
divide each group of patients into cohorts with signiﬁcantly
different PFS and OS rates (Figure 5). In the validation set, patients
with GCB and non-GCB subtypes according to our algorithm did
not differ signiﬁcantly in terms of clinical characteristics at
presentation, except for age that was signiﬁcantly higher for
patients with non-GCB subtype.
Univariate and multivariate analyses
As shown in Table 3, univariate analysis for PFS and OS revealed
that high IPI score, all the variables that compose the IPI (that is,
stage, age, lactate dehydrogenase, performance status and
number of extra nodal sites) and failure to achieve CR were
signiﬁcantly associated with shorter PFS. In multivariate analysis
using the Cox regression model, an IPI score 3–5 (hazard ratio,
0.59; 95% CI, 0.43–0.83; P¼ 0.002), non-GCB origin (hazard ratio,
0.59; 95% CI, 0.43–0.81; P¼ 0.001) and failure to achieve CR
(hazard ratio, 0.15; 95% CI, 0.10–0.21; P¼ 0.032) were independent
adverse prognostic factors for PFS. Similar results were obtained in
terms of OS, with IPI score 3–5 (hazard ratio, 0.53; 95% CI,
0.38–0.74; P¼ 0.0002), non-GCB origin (hazard ratio, 0.56; 95% CI,
0.40–0.77; P¼ 0.0004) and failure to achieve CR (hazard ratio, 0.14;
95% CI, 0.10–0.20; Po0.0001) as independent prognostic factors.
Age, stage, lactate dehydrogenase, performance status and
number of extra nodal sites were not computed in the multi-
variate analysis because these variables are included in the IPI
score. More interestingly, univariate and multivariate analysis were
performed in the 237 patients treated with R-CHOP of the
validation set. Similarly to the former, both IPI score 3–5 (hazard
ratio, 0.57; 95% CI, 0.37–0.89; P¼ 0.01), and non-GCB origin
(hazard ratio, 0.63; 95% CI, 0.42–0.96; P¼ 0.03) resulted indepen-
dent adverse prognostic factors for PFS.
Kaplan–Meier analyses showed that, according to our algorithm,
IPI score (0–1 vs 2–3 vs 4–5) could divide patients with GCB and
non-GCB subtypes into cohorts with signiﬁcantly different PFS
rates (Supplementary Figure 3). When we combined the IPI score
and our algorithm, we identiﬁed a group of patients with a very
favorable PFS (IPI 0–1 and GCB phenotype, 5-year PFS of 86±1%)
and a patient group with an unfavorable PFS (IPI score 4–5 and
non-GCB phenotype, 5-year PFS of 28±7%).
Twenty-three of 296 patients (8%) had MYC rearrangements.
Patients with MYC breaks had a signiﬁcantly inferior OS (P¼ 0.03)
and PFS (P¼ 0.01) compared with patients without breaks
(median and mean OS 24 and 34 months, median and mean
PFS 18 and 25 months, respectively). As shown in Table 3,
MYC breaks were signiﬁcantly more frequent among patients with
GCB–DLBCL. Even though numbers were low, the pejorative
impact of MYC breaks on survival of our patients reached
statistical signiﬁcance in GCB patients according to GEP
(16 patients, P¼ 0.02 for OS and Po0.0001 for PFS) but not in
ABC (7 patients, P¼ 0.32 for OS and P¼ 0.66 for PFS). Similar
results were obtained when we used our algorithm to split
patients into GCB (17 patients, P¼ 0.03 for OS and Po0.0001 for
PFS) or non-GCB phenotype (6 patients, P¼ 0.43 for OS and
P¼ 0.76 for PFS).
DISCUSSION
We designed a new algorithm based on the expression of CD10,
FOXP1 and BCL6 that precisely stratiﬁes the GCB and ABC
subtypes of DLBCL. The associations of each marker with GCB or
ABC-DLBCL and the cutoffs to determine positivity were assessed
using ROC curves, which obviated the need to use any arbitrary
cutoffs. Our algorithm had strong prognostic power matching that
of GEP in R-CHOP-treated patients and was independent of IPI.
In an independent cohort of patients treated with either CHOP or
R-CHOP, we conﬁrmed the algorithm’s prognostic predictive
value. Finally, the algorithm proposed also allowed us to classify
patients with DLBCL whose disease had been unclassiﬁable
according to GEP, although survival analysis in this small group
of patients did not reach statistical signiﬁcance.
Our results conﬁrm the reliability of previous ﬁndings,33
demonstrating that GEP can be performed by extracting RNA
from formalin-ﬁxed, parafﬁn-embedded tissue instead of frozen
tissue, which is often not obtained at diagnosis and is becoming
decreasingly available in the current era of small needle biopsy for
diagnosis. The immunohistochemical algorithm can be easily
performed by most laboratories on parafﬁn-embedded tissues
and allows for the direct visualization of tumor cells.26 Moreover,
compared with GEP analysis, the phenotype of the tumor reﬂects
gene expression of the lymphoma cells, revealing which
Table 2. Summary of biostatistical features of five immunohistochemical stains (CD10, GCET1, MUM1, FOXP1 and BCL6)
Molecule Mean/
median
Distribution Youden’s
index
cutoff
PFS
OS
p
vs4
Algorithm
cutoff
PFS
OS
p
vs4
25th
percentile
PFS
OS
p
vs4
50th
percentile
PFS
OS
p
vs4
75th
percentile
PFS
OS
p
vs4
CD10 37/20 35 0.06 30 0.03 0 0.01 20 0.02 80 0.43
0.06 0.06 0.03 0.08 0.88
GCET1 32/5 45 0.01 60 0.02 0 0.001 5 0.006 80 0.07
0.06 0.07 0.01 0.07 0.20
FOXP1 58/80 75 0.01 60 0.006 5 0.01 80 0.02 100 0.21
0.0004 0.0009 0.03 0.03 0.10
MUM1 42/30 58 0.009 60 0.009 5 0.76 30 0.22 80 0.05
0.01 0.02 0.12 0.01 0.42 0.42
BCL6 60/70 33 0.39 30 0.38 40 0.20 70 0.51 90 0.85
0.66 0.51 0.68 0.29 0.98
Abbreviations: BCL6, B-cell lymphoma 6; CD10, neprilysin or common acute lymphocytic leukemia antigen, CALLA; FOXP1, forkhead box protein P1; GCET1,
germinal center expressed transcript 1; MUM1, multiple myeloma oncogene 1; OS, overall survival; PFS, progression-free survival. The x axis of the histogram
represents the percentage of positive staining from 0 to 100%, divided in 10% intervals; the y axis is the relative number of patients. For CD10 and GCET1
higher values had positive effect on PFS; for FOXP1 and MUM1 higher values were associated with inferior PFS. Percentiles were used for all the molecules to
address the non-Gaussian distribution of values, and their effect at different levels on PFS and OS.
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molecules are in fact expressed and functional and could thus be
the target of new drugs. Recent studies have shown that
some drugs enhance the activity of chemotherapy in ABC–but
not GCB–DLBCL–providing a rationale for different therapeutic
approaches for distinct DLBCL subtypes.34–38
Malignant B cells of DLBCL are thought to be ‘frozen’ at
particular stages of B-cell development. In the GC microenviron-
ment, speciﬁc proteins are up or downregulated at any one
particular stage. It has been shown that B cells in the GC can
migrate extensively within their respective compartments.39 In this
scenario, GCET1 stains positive in rapidly dividing B cells (that is,
Ki-67þ centroblasts) in the dark zone of the GC. Its expression is
enhanced when B cells are stimulated by CD40 signaling40 and it
is then likely to identify centroblasts that have been rescued from
cell death and are prompted to proliferate and undergo somatic
hypermutation and class-switch recombination.17,28,41 Foxp1 is an
essential transcriptional regulator of B-cell development that
inﬂuences B-cell development at very early stages,42 and its mRNA
expression is also typically elevated in ABC-DLBCL.42 Cell lines that
are at an intermediate stage of differentiation between GCB and
ABC (that is, LIB) express CD10, BCL6 and MUM1 as well as
FOXP1,19 indicating that this marker could represent a bridge from
the GC stage to subsequent B-cell activation. Some preliminary
data have suggested that smaller FOXP1 isoforms may have a
role in activating the transcription factor MUM1, pushing
B cells toward plasma cell differentiation.6,41–44 Hence, in the
construction of our algorithm, we evaluated the expression of
CD10, GCET1, FOXP1 and MUM1 in that order to progressively
address the steps of B-cell maturation.
As BCL6 is the marker with the largest variability in its staining
and interpretation between laboratories, only a minority of
patients will need to rely on its staining for subset discrimination.
According to our algorithm, the role of BCL6 is conﬁned to
patients (less than 20%) that are negative both for CD10 and
FOXP1, while the Choi and the Hans algorithms gave strong
decisional power to BCL6 (50% and 60% of patients, respectively).
We acknowledge that the assignment of these patients to a
speciﬁc subset might beneﬁt of other GC-speciﬁc markers that
Table 3. Clinical characteristics and their impact on survival of 475 DLBCL treated with R-CHOP, then stratified according to our three-marker
algorithm as GCB or non-GCB.
Overall OS P-value GCB Non-GCB P-value
N % PFS P-value N % N %
Patients 475 100
Median age 62
Z60 289 61 0.004 o0.0001 135 53 154 70 0.0002
o60 186 39 119 47 67 30
Gender
F 202 43 0.33 0.80 107 42 95 43 0.84
M 273 57 147 58 126 57
Stage
I–II 224 47 o0.0001 o0.0001 131 52 93 42 0.04
III–IV 251 53 123 48 128 58
LDH
Normal 149 35 0.0001 o0.0001 80 36 69 33 0.46
High 280 65 140 64 140 67
Performance Status
0–1 378 80 0.003 o0.0001 198 78 180 81 0.35
2 or more 97 20 56 22 41 19
N extra nodal sites
0–1 366 77 0.001 o0.0001 199 78 167 76 0.47
2 or more 109 23 55 22 54 24
B symptoms
No 281 68 0.19 0.06 153 70 128 66 0.40
Yes 132 32 66 30 66 34
IPI risk group
0–1 172 46 o0.0001 o0.0001 102 47 70 33 0.002
2–3 198 40 94 42 104 50
4–5 59 14 22 10 37 17
Bulky mass
o7.5 cm 271 73 0.86 0.10 136 71 135 75 0.36
Z7.5 cm 99 27 55 29 44 25
C-MYC breaks
No 273 92 0.01 0.03 129 88 144 96 0.01
Yes 23 8 17 12 6 4
Therapy response
CR 358 76 o0.0001 o0.0001 187 74 171 77 0.34
PR 72 15 40 16 32 15
SD 20 4 13 5 7 3
Abbreviations: CR, complete response; GCB, germinal center B-cell like; LDH, lactate dehydrogenase; OS, overall survival; PFS, progression-free survival;
PR, partial response. Data regarding the presence of B symptoms, bulky disease, LDH, IPI risk group were available for 413, 370 and 429 patients, respectively.
MYC analysis was performed in 296 classified patients. The reported P-value on the IPI score distribution refers to the difference between low (0–1) and high
(4–5) IPI score; P-values were P¼ 0.13 between intermediate (2–3) and high (4–5), and P¼ 0.02 between low (0–1) and intermediate (2–3) IPI scores. For therapy
response we calculated P-values as CR vs other responses.
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have been used in other algorithms, but were not analyzed in our
study. Among these, human GC-associated lymphoma (HGAL or
GCET1) expression has been shown to correlate with improved
survival in CHOP-treated patients with DLBCL.45 This observation
was conﬁrmed in our series of cases as well (data not shown).
Similarly, LMO2 mRNA expression was reported as a predictor of
superior outcome in DLBCL patients in a relatively small series of
DLBCL cases, however, the ﬁnding has not been conﬁrmed and
validated from other groups in a large cohort of cases.46 HGAL is
an adapter protein involved in prevention of lymphocyte
migration, thus constraining lymphocytes to the GC.47,48 Double-
staining studies have demonstrated that most BCL6þ cells
co-express HGAL, although several BCL6þ cells of the
proliferating pole or dark zone of GCs lack staining for HGAL.
Therefore, it is suggested that HGAL, unlike GCET1, may identify
resting cells within the GC.49,50 Other markers that are
discriminatory for ABC-DLBCL, such as cyclin D2,9,51 PRDM1/
Blimp1 and XBP1,52 were excluded based on our previous
experience and on the absence of data in R-CHOP-treated
patients at the time of the approval for the current study. We
found that GCET1 and FOXP1 were both predictive of PFS in
R-CHOP-treated patients, regardless of the cutoff utilized (Table 1).
To the best of our knowledge, this is the ﬁrst report addressing the
prognostic predictive value of GCET1 expression as a single
marker for R-CHOP-treated patients with DLBCL.
The use of the algorithm we propose, when applied to patients
uniformly treated with R-CHOP, had remarkable prognostic
signiﬁcance and was independent of IPI, as shown in the
multivariate analysis. When we combined the IPI score and our
algorithm, we could identify cohorts of patients at very low
(IPI 0–1 and GCB phenotype, 5-year PFS of 86±1%) or very high
risk of relapse (IPI score 4–5 and non-GCB phenotype, 5-year PFS
of 28±7%).
The staining algorithm proposed by Choi et al.12 has shown good
concordance with GEP analysis, but had a complicated structure,
using ﬁve markers with different cutoffs. The more recent
‘Tally algorithm’16 was also based on the expression of ﬁve
biomarkers, three of which are not commonly used by
pathologists, and with arbitrary decisional cutoffs. In both studies,
it is not clear whether patients with transformed, primary
mediastinal, primary cutaneous or central nervous system DLBCL
were excluded from the analysis, despite the peculiar biological
features and clinical behavior of these tumor types.
Unlike any other new marker, CD10 is part of the initial
immunophenotypic panel used by hematopathologists. Therefore,
our use of CD10 as the ﬁrst discriminating marker in the new
algorithm simpliﬁes the categorization of patients. The predictive
value of CD10 positivity alone in identifying patients with GCB
according to GEP was 95% in our series, similar to that reported by
others,9,12,20 and could not be improved by the addition of any
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Figure 4. OS and PFS analyses of R-CHOP-treated DLBCL patients when stratified by GEP and TMA immunohistochemistry algorithm. (a) OS
curve for all patients. (b) PFS curve for all patients. (c, d) OS and PFS curves of 431 patients stratified by GEP results, excluding unclassifiable
cases (44 of 475); unclassifiable cases are analyzed separately in Supplementary Figure 1. (e, f ) OS and PFS curves of 475 patients divided into
GCB and non-GCB according to our TMA algorithm.
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other markers. Thus, although we have maintained the structure
of the Hans algorithm for CD10þ patients, our new algorithm
improves the discrimination of CD10 patients, who were
correctly assigned in 91.4% of cases, compared with 82.3%
when the Hans algorithm was used. However, a very small subset
of cases with strong CD10 expression was classiﬁed as ABC. Most
of these cases had strong FOXP1 or MUM1 expression, but rarely
expressed GCET1. On the other hand rare cases lacking CD10
expression were classiﬁed as GCB by GEP. Most of these cases had
strong BCL6 and FOXP1 expression, while only few expressed
GCET1. Morphologically, the ﬁrst group had polymorphic
morphology, whereas cases classiﬁed as ABC by IHC algorithm,
but GCB by GEP analysis, showed typical centroblastic
morphology. The low number of misclassiﬁed patients did not
allow conclusion on clinical behavior of this particular subset.
We analyzed 296 patients with available material for the
presence of MYC, and 8% had MYC rearrangements. Patients with
MYC breaks had a signiﬁcantly inferior outcome compared with
patients without breaks. Although numbers were low, MYC breaks
had a signiﬁcant impact on survival of GCB, but not in
ABC patients, either when recognized by means of GEP or of
our algorithm.
We reviewed 466 patients with available material for morpho-
logical classiﬁcation using 2008 WHO classiﬁcation as criteria.53–55
Four hundred and ﬁve (87%) had centroblastic morphology.
Of them, 251 had cleaved (59) or large noncleaved (192) cell types.
Twenty-four patients had anaplastic morphology (5%) and 37 had
immunoblastic morphology (IB, 8%). According to morphological
subtype distribution, centroblastic morphology was signiﬁcantly
more represented in the GCB (54%) than IB (27%, P¼ 0.001), while
anaplastic morphology was GCB in 66%. Large noncleaved cell
type was more represented in GCB (63%), similarly to the medium-
sized cells (76%), and differently from cleaved cells (41%) and
polymorphic cell type (38%). Patients with centroblastic
morphology had signiﬁcantly better OS (Po0.0001) and PFS
(P¼ 0.001) compared with IB or anaplastic morphology
(P¼ 0.0001 and P¼ 0.004, respectively). According to cell type
distribution, large noncleaved cell type had the better 5-year PFS
and OS (65% and 70%, respectively). A signiﬁcant difference in
terms of OS or PFS was observed between large noncleaved cell
type and others (P¼ 0.04 and P¼ 0.005, respectively).
In conclusion, we found that the expression of three markers
can be combined to divide DLBCL into GCB and non-GCB
subgroups with high speciﬁcity and that our method can predict
an outcome similar to that of GEP analysis in R-CHOP-treated
patients. Our ﬁndings are currently used in our new clinical trial
DLBCL studies. We believe the algorithm presented here will
substantially improve upon the performance of the former
algorithms, and allow a better stratiﬁcation of DLBCLs for further
characterizing the pathways that identify each of the DLBCL
subtypes and for testing the efﬁcacy of new drugs in distinct
subgroups.
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Figure 5. Validation set of OS and PFS analyses in 574 patients with DLBCL treated with cyclophosphamide, doxorubicin, vincristine,
prednisone (CHOP) and R (Rituximab)-CHOP. OS and PFS analysis of 574 patients with available TMA but not GEP analysis, stratified according
to our three-marker algorithm. (a) 337 CHOP-treated patients; (b) 237 R-CHOP treated patients.
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and 1RC1CA146299). Publicly available data sets: All primary sequencing data will be
made publicly available through the GEO archive through accession GSE#31312.
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